Top 26 Biodefense Companies
Top 26 Biodefense Companies
The biodefense industry focuses on protecting populations from biological threats, including infectious diseases and bioterrorism. Companies within this sector develop medical countermeasures, diagnostics, and technologies to combat pathogens and enhance public health security. As global health challenges grow, with pandemics looming and bioterrorism risks increasing, demand for innovative solutions is rising. Advancements in vaccine development, pathogen detection, and response capabilities are increasingly adaptive. Consequently, the industry is poised for growth, driven by research and public sector investment, particularly in response to emerging biological threats.
The companies listed here vary in size, with most established since the late 20th century. Headquartered across both the United States and various countries in Europe, these firms focus on biodefense capabilities such as vaccine production, diagnostics, and consulting services. Companies like BioFire Defense and Elusys Therapeutics exemplify innovative approaches to national security. This global industry showcases a mix of private biotechnology firms and corporate entities, all striving to address significant health challenges with cutting-edge products and solutions.
Read on to discover the top biodefense companies.
Top 26 Biodefense Companies
1. BioFire Defense
- Website: biofiredefense.com
- Ownership type: Private
- Headquarters: Salt Lake City, Utah, United States (USA)
- Employee distribution: United States (USA) 100%
- Founded year: 1990
- Headcount: 51-200
- LinkedIn: biofire-defense
BioFire Defense, based in Salt Lake City, Utah, is a private biotechnology firm founded in 1990. The company specializes in advanced biological agent identification systems, catering primarily to military and government agencies. Their flagship products include the BioFire FilmArray and RAZOR Mk II systems, which facilitate rapid detection of pathogens, ensuring safety and operational readiness in critical scenarios. BioFire Defense has established a strong presence in the biodefense industry, having been awarded significant contracts such as the Joint Biological Agent Identification and Diagnostic System (JBAIDS) and the Next Generation Diagnostic System (NGDS) by the U.S. Department of Defense. These systems are crucial for identifying biological warfare agents and other pathogens, underscoring the company's role in enhancing national security. BioFire's innovative approach and commitment to developing effective biodefense solutions make it a notable entity in this field.
2. Elusys Therapeutics, Inc.
- Website: elusys.com
- Ownership type: Corporate
- Headquarters: Parsippany-Troy Hills, New Jersey, United States (USA)
- Employee distribution: United States (USA) 100%
- Latest funding: December 2021
- Founded year: 1998
- Headcount: 11-50
- LinkedIn: elusys-therapeutics-inc
Elusys Therapeutics, Inc., based in Parsippany-Troy Hills, New Jersey, is a biopharmaceutical company founded in 1998. The firm specializes in developing medical countermeasures aimed at infectious diseases, with a particular emphasis on anthrax. Their flagship product, ANTHIM® (obiltoxaximab), is a monoclonal anthrax antitoxin that has been licensed for use in the United States, Canada, and Great Britain. Elusys has received over $400 million in contracts from various government entities, including the Biomedical Advanced Research and Development Authority (BARDA) and the Department of Defense (DoD), to support the development and procurement of ANTHIM®. This product is included in the U.S. Strategic National Stockpile, which is crucial for responding to potential bioterrorism threats. In 2022, Elusys was contracted to supply ANTHIM® to the Public Health Agency of Canada, further demonstrating its active role in enhancing public health preparedness against biological threats.
3. Tunnell Government Services, Inc.
- Website: tunnellgov.com
- Ownership type: Private
- Headquarters: Bethesda, Maryland, United States (USA)
- Employee distribution: United States (USA) 100%
- Founded year: 1962
- Headcount: 51-200
- LinkedIn: tunnell-government-services
Tunnell Government Services, Inc. is a consulting firm based in Bethesda, Maryland, founded in 1962. The company operates as a subsidiary of Tunnell Consulting, Inc. and has carved out a niche in providing specialized consulting services to government agencies. Their expertise lies in public health preparedness, biodefense lab support, and scientific project portfolio management. Tunnell collaborates with various federal entities, including the Department of Health and Human Services (HHS) and the Department of Defense (DoD), to enhance operational effectiveness in addressing health threats. They engage in biomedical research, focusing on infectious diseases and medical countermeasures, and have been involved in significant projects that support the U.S. government's biodefense strategies. Their team includes highly qualified professionals with extensive experience in scientific research and project management, enabling them to deliver tailored solutions to complex health challenges.
4. Fabentech
- Website: fabentech.com
- Ownership type: Venture Capital
- Headquarters: Lyon, Auvergne-Rhône-Alpes, France
- Employee distribution: France 100%
- Latest funding: Other (Debt), $21.9M, October 2024
- Founded year: 2009
- Headcount: 11-50
- LinkedIn: fab%27entech
Fabentech, founded in 2009 and based in Lyon, France, is a biopharmaceutical company focused on immunotherapy solutions for emerging infectious diseases and biodefense. The company has developed treatments for significant health threats, including H5N1 avian influenza, COVID-19, and Ebola. Fabentech collaborates with various governments and healthcare organizations to bolster public health security. Their innovative approach includes the production of highly purified polyclonal antibodies, which are designed to neutralize specific pathogens effectively. Recently, Fabentech has received substantial funding, including €7.7 million from the European Commission, to develop a broad-spectrum therapy against emerging viruses. Their commitment to biodefense is further demonstrated through ongoing projects aimed at creating antidotes for plant-based toxins categorized as high-priority biothreats. This strategic focus positions Fabentech as a significant player in the field of biodefense.
5. Mapp Biopharmaceutical Inc
- Website: mappbio.com
- Ownership type: Private
- Headquarters: San Diego, California, United States (USA)
- Employee distribution: United States (USA) 100%
- Latest funding: Other (Grant), $16.5M, June 2019
- Founded year: 2003
- Headcount: 51-200
- LinkedIn: mapp-biopharmaceutical-inc
Mapp Biopharmaceutical Inc, founded in 2003 and based in San Diego, California, is a biopharmaceutical company focused on creating novel therapeutics for infectious diseases. The company specializes in monoclonal antibody therapies, which are crucial for combating serious viral threats. Mapp collaborates with various government agencies and healthcare organizations to address significant health challenges, particularly in the field of biodefense. Their recent projects include developing treatments for the Marburg virus and conducting human trials for a monoclonal antibody targeting the Nipah virus. Mapp has received funding, including a notable grant of $16.5 million in June 2019, to support their research and development efforts. This funding underscores their active engagement in advancing biodefense solutions.
6. BioFactura, Inc.
- Website: biofactura.com
- Ownership type: Corporate
- Headquarters: Frederick, Maryland, United States (USA)
- Employee distribution: United States (USA) 100%
- Latest funding: Other (Grant), $1.0M, July 2020
- Founded year: 2003
- Headcount: 11-50
- LinkedIn: biofactura-inc-
BioFactura, Inc. is a biopharmaceutical company based in Frederick, Maryland, founded in 2003. The company is dedicated to developing and manufacturing high-value biosimilars and biodefense medical countermeasures. BioFactura focuses on innovative drug development to meet critical medical needs, particularly in the areas of smallpox and Marburg therapeutics. Their clientele includes government agencies and healthcare organizations that seek effective treatments against biological threats. BioFactura has made significant strides in the biodefense sector, recently securing a $67.4 million advanced development contract for its smallpox therapeutic, underscoring its role in addressing national security concerns related to biological agents. The company utilizes its proprietary StableFast™ Biomanufacturing Platform to enhance the efficiency and quality of its drug production processes, further solidifying its position in the biopharmaceutical industry.
7. Greffex, Inc.
- Website: greffex.com
- Ownership type: Private
- Headquarters: Aurora, Colorado, United States (USA)
- Employee distribution: United States (USA) 100%
- Founded year: 1999
- Headcount: 11-50
- LinkedIn: greffex-inc-
Greffex, Inc. is a biotechnology firm based in Aurora, Colorado, founded in 1999. The company specializes in genetic engineering and vaccine development, utilizing its proprietary GreVac technology to create innovative vaccines aimed at infectious diseases, including COVID-19 and avian flu. Greffex has established itself as a key player in the biodefense sector by securing a contract worth up to $18.9 million from the National Institute of Allergy and Infectious Diseases. This funding supports the development of vaccine candidates that address both natural and man-made infectious threats. Greffex's approach emphasizes rapid production and distribution, making it a vital contributor to public health organizations seeking effective solutions for disease prevention. The company is currently advancing several vaccine candidates through clinical trials, including those for avian flu and a universal flu vaccine, showcasing its commitment to tackling pressing health challenges.
8. Signature Science, LLC
- Website: signaturescience.com
- Ownership type: Corporate
- Headquarters: Austin, Texas, United States (USA)
- Employee distribution: United States (USA) 100%
- Latest funding: $52.5M, November 2010
- Founded year: 2001
- Headcount: 201-500
- LinkedIn: signature-science-llc
Signature Science, LLC, founded in 2001 and based in Austin, Texas, is a scientific consulting firm that provides a range of technical solutions in forensic science, genomic technologies, and bioinformatics. The company serves both government and commercial clients, focusing on critical areas such as health security, public safety, and national security. Their offerings include forensic DNA casework, advanced chemical detection solutions, and comprehensive training services, all underscored by a commitment to scientific rigor and quality assurance. Signature Science plays a pivotal role in biodefense through its expertise in biosecurity and emerging threats, particularly in the rapid identification and characterization of biological agents. They have been involved in significant projects, including those funded by the Intelligence Advanced Research Projects Activity (IARPA) and the Biomedical Advanced Research and Development Authority (BARDA), which aim to enhance public health responses to biological threats. Their work not only supports law enforcement and national defense but also contributes to the broader public health landscape, making them a notable player in the biodefense industry.
9. Zeteo Tech, Inc.
- Website: zeteotech.com
- Ownership type: Private
- Headquarters: Sykesville, Maryland, United States (USA)
- Employee distribution: United States (USA) 100%
- Latest funding: Other (Grant), $256,000, August 2021
- Founded year: 2013
- Headcount: 11-50
- LinkedIn: zeteo-tech-inc
Zeteo Tech, Inc., founded in 2013 and based in Sykesville, Maryland, is a private company specializing in biodefense and medical device technologies. With a team of 23 employees, Zeteo Tech focuses on advanced biological mass spectrometry, offering products such as the digitalMALDI® mass spectrometers and BreathBiomics™ sampling systems. These technologies are designed for the rapid diagnosis of diseases and detection of biological threats, making them crucial for public health and safety. The company has received funding from notable sources, including the U.S. Department of Defense and the Department of Homeland Security, to develop systems that can identify aerosolized bio-threats in real-time. Their innovative solutions aim to enhance disease screening and bio-threat detection capabilities, addressing critical needs in biodefense. Zeteo Tech's commitment to advancing technology in this field is further evidenced by their recognition as a 2020 Tibbetts Award winner, highlighting their achievements in creating cutting-edge technologies for biodefense applications.
10. Bharat Biotech
- Website: bharatbiotech.com
- Ownership type: Venture Capital
- Headquarters: Hyderabad, Telangana, India
- Employee distribution: India 99%
- Latest funding: Other (Grant), $14.1M, June 2020
- Founded year: 1996
- Headcount: 1001-5000
- LinkedIn: bharat-biotechil
Bharat Biotech International Limited, founded in 1996 and based in Hyderabad, India, is a biotechnology company that specializes in the development and manufacturing of vaccines and biotherapeutics. With a workforce of over 1,800 employees, the company is dedicated to providing innovative solutions to combat infectious diseases, particularly in developing nations. Bharat Biotech has a robust research and development pipeline, owning more than 220 patents and producing vaccines that have reached over 125 countries. Their notable products include COVAXIN, an indigenous COVID-19 vaccine, and ROTAVAC, a vaccine for rotavirus. The company has received funding, including a grant of $14.1 million in June 2020, which supports their ongoing research efforts. Bharat Biotech's manufacturing facilities are approved by global health authorities, including the USFDA and WHO, ensuring that their products meet international safety and quality standards.
11. ELT Group
- Website: eltgroup.net
- Ownership type: Private
- Headquarters: Rome, Lazio, Italy
- Employee distribution: Italy 98%, Other 2%
- Founded year: 1951
- Headcount: 501-1000
- LinkedIn: elettronica-group
ELT Group, based in Rome, Italy, is a private defense technology company founded in 1951. With a workforce of approximately 1,451 employees, the company specializes in electromagnetic spectrum operations and cybersecurity solutions. ELT Group serves military and defense organizations, government agencies, and private sector clients, focusing on enhancing safety and security across various domains. Notably, the company has expanded its expertise into biodefense, developing innovative technologies aimed at inactivating respiratory viruses, including COVID-19. Their E4SHIELD technology exemplifies this commitment, utilizing electromagnetic waves to neutralize viral threats in real-time. Additionally, ELT Group has established E4LIFE in partnership with Lendlease, marking a significant step in the biodefense sector. The company is also involved in space protection solutions, showcasing its multifaceted approach to addressing complex challenges in defense and security.
12. Serum Institute of India Pvt. Ltd.
- Website: seruminstitute.com
- Ownership type: Private
- Headquarters: Pune, Maharashtra, India
- Employee distribution: India 100%
- Founded year: 1966
- Headcount: 1001-5000
- LinkedIn: serum-institute-of-india-limited
Serum Institute of India Pvt. Ltd., founded in 1966 and based in Pune, Maharashtra, is a prominent vaccine manufacturer specializing in immuno-biologicals. The company produces a wide array of vaccines targeting various infectious diseases, catering to both domestic and international markets. With a workforce of over 5,000 employees, Serum Institute is dedicated to research and development, continuously working to improve vaccine efficacy and safety. Notably, the company has been instrumental in the global response to the COVID-19 pandemic through its production of COVISHIELD, a widely used vaccine. Their commitment to public health is further demonstrated by their efforts to supply vaccines to developing countries, addressing critical health challenges. Serum Institute's operations reflect a strong focus on innovation and accessibility in the field of immunization.
13. PHC Global
- Website: phcglobal.com
- Ownership type: Private
- Headquarters: United States (USA)
- Employee distribution: United States (USA) 100%
- Founded year: 2020
- Headcount: 51-200
- LinkedIn: the-public-health-company
PHC Global, founded in 2020 and based in Palo Alto, California, is a private company specializing in biosecurity intelligence. The firm offers innovative solutions for early biothreat detection and analysis, primarily through its Pharos Platform. This platform provides organizations with tools to monitor and manage risks associated with biological threats, ensuring the safety of employees and the continuity of business operations. PHC Global serves a variety of enterprises and organizations focused on risk management and security, delivering critical insights and recommendations to help them navigate the complexities of biosecurity. Their approach combines advanced data science and AI technology to provide timely alerts and contextualized risk assessments, making them a relevant player in the biodefense sector.
14. Proengin
- Website: proengin.com
- Ownership type: Private Equity
- Headquarters: Les Mesnuls, Île-De-France, France
- Employee distribution: France 94%, India 2%, United Arab Emirates 2%, Other 2%
- Latest funding: December 2020
- Founded year: 1972
- Headcount: 51-200
- LinkedIn: proengin
Proengin, founded in 1972 and based in Les Mesnuls, Île-De-France, France, specializes in CBRN security solutions. The company develops, manufactures, and markets a comprehensive range of detection systems for chemical and biological threats. Their products serve military forces, first responders, and critical infrastructure sectors, providing essential tools for threat detection and management. Proengin's technology is particularly noted for its flame spectrophotometry, which enables the detection of various chemical and biological agents at low concentrations. The company has established a significant presence in over 70 countries, with an installed base of more than 19,000 detectors worldwide. Proengin also offers maintenance services and training to ensure effective use of their technology, further solidifying their role in the biodefense industry.
15. Centivax
- Website: centivax.com
- Ownership type: Venture Capital
- Headquarters: South San Francisco, California, United States (USA)
- Employee distribution: United States (USA) 100%
- Latest funding: Seed, $10.0M, November 2022
- Founded year: 2020
- Headcount: 11-50
- LinkedIn: centivax
Centivax, founded in 2020 and based in South San Francisco, California, is a biotechnology firm dedicated to the research and development of vaccines and therapeutics for infectious diseases. The company is particularly focused on creating broad-spectrum vaccines that can provide protection against multiple strains of viruses, including influenza. Their first broad-spectrum vaccine is currently in pre-clinical development, with promising results in animal models. Centivax has garnered attention for its innovative approach, receiving a Gates Foundation Grand Challenge award aimed at ending pandemic threats. The company is also involved in developing broad-spectrum anti-infectives to address the growing issue of multidrug-resistant bacteria. With a recent funding round of $10 million in November 2022, Centivax is positioned to advance its clinical trials and expand its research efforts. Their partnerships with notable institutions, including the U.S. Naval Medical Research Center, underscore their commitment to addressing global health challenges.
16. AstriVax Therapeutics
- Website: astrivax.com
- Ownership type: Private Equity
- Headquarters: Leuven, Flanders, Belgium
- Employee distribution: Belgium 100%
- Latest funding: Other (Grant), $3.2M, December 2023
- Founded year: 2022
- Headcount: 11-50
- LinkedIn: astrivax
AstriVax Therapeutics is a clinical-stage biopharmaceutical company based in Leuven, Belgium, founded in 2022. The company specializes in the development of innovative DNA-based vaccines aimed at combating infectious diseases. With a focus on addressing significant public health challenges, AstriVax targets diseases such as Hepatitis B and Human Papilloma virus, among others. Their patented technology platform, known as the Plasmid-Launched Live Attenuated Virus (PLLAV), allows for the creation of vaccines that are not only effective but also thermostable, which is crucial for distribution in various environments. AstriVax has recently secured funding of approximately €3.2 million through a grant, which will support their ongoing research and development efforts. The company is committed to building a robust pipeline of vaccines that can provide both prophylactic and therapeutic solutions to emerging viral threats.
17. Auro Vaccines LLC
- Website: aurovaccines.com
- Ownership type: Corporate
- Headquarters: Pearl River, New York, United States (USA)
- Employee distribution: India 100%
- Latest funding: $11.3M, November 2019
- Founded year: 2021
- Headcount: 11-50
- LinkedIn: auro-vaccines-llc
Auro Vaccines LLC, based in Pearl River, New York, is a biotechnology firm founded in 2021. The company specializes in the development of innovative vaccines targeting infectious diseases and cancers. Utilizing their proprietary PBS Vax™ platform, Auro Vaccines tailors immune responses to meet specific health challenges. Their pipeline includes vaccines for Ebola and Marburg viruses, which have received substantial federal funding and are licensed to Emergent BioSolutions for further development. Additionally, they are working on a Nipah/Hendra virus vaccine currently in Phase I clinical evaluation, alongside other prophylactic vaccines for SARS CoV-2 and Chikungunya virus. Auro Vaccines actively collaborates with healthcare organizations and government agencies, demonstrating their commitment to advancing vaccine solutions for public health and biodefense.
18. Porton Biopharma Ltd
- Website: portonbiopharma.com
- Ownership type: Private
- Headquarters: Salisbury, England, United Kingdom (UK)
- Employee distribution: United Kingdom (UK) 100%
- Founded year: 2015
- Headcount: 51-200
- LinkedIn: porton-biopharma
Porton Biopharma Ltd, established in 2015 and based in Salisbury, England, is a biopharmaceutical company dedicated to developing and manufacturing life-saving therapeutics and vaccines. The company operates from specialized facilities that ensure compliance with stringent regulatory standards. Porton Biopharma is notable for being the sole manufacturer of Erwinase, an enzyme used in treating Acute Lymphoblastic Leukaemia, and the UK’s licensed anthrax vaccine. Their products are crucial for both patient care and national security, as they serve healthcare providers and government entities. The company’s expertise in microbial fermentation and commitment to quality assurance further solidify its role in the biopharmaceutical industry, particularly in the context of biodefense.
19. Baseimmune
- Website: baseimmune.co.uk
- Ownership type: Venture Capital
- Headquarters: London, England, United Kingdom (UK)
- Employee distribution: United Kingdom (UK) 100%
- Latest funding: Series A, $11.4M, February 2024
- Founded year: 2019
- Headcount: 11-50
- LinkedIn: baseimmune
Baseimmune is a biotechnology firm based in London, UK, founded in 2019. The company specializes in the development of innovative vaccines, particularly focusing on creating mutation-proof vaccines through the use of advanced AI-driven design algorithms. Their technology aims to tackle the challenges posed by rapidly evolving pathogens, which are a significant concern for public health and pandemic preparedness. Baseimmune serves healthcare organizations and governments, striving to enhance pandemic readiness and improve health outcomes globally. The company has an early-stage pipeline that includes vaccine candidates for malaria, a pancoronavirus vaccine, and a veterinary vaccine against African swine fever. Recently, Baseimmune raised £9 million in Series A funding to further develop their vaccine candidates and expand their technological capabilities. This funding will enable them to accelerate their research and development efforts, positioning them as a proactive player in the field of vaccine innovation.
20. Apriori Bio
- Website: aprioribio.com
- Ownership type: Venture Capital
- Headquarters: Boston, Massachusetts, United States (USA)
- Employee distribution: United States (USA) 100%
- Latest funding: Other (Grant), $1.1M, July 2024
- Founded year: 2020
- Headcount: 11-50
- LinkedIn: apriori-bio
Apriori Bio, founded in 2020 and based in Boston, Massachusetts, is a biotechnology firm dedicated to creating vaccines that can withstand the rapid evolution of viruses. The company employs a unique technology platform that enables them to analyze existing and potential viral variants, allowing for the design of vaccines that can preemptively address future threats. Apriori Bio has received significant funding, including a recent grant of $1.1 million in July 2024, which supports their mission to enhance public health responses to viral outbreaks. Their innovative approach positions them as a key player in the biodefense sector, focusing on the intersection of advanced science and public health needs.
21. ANP Technologies, Inc.
- Website: anptinc.com
- Ownership type: Private
- Headquarters: United States (USA)
- Employee distribution: United States (USA) 100%
- Founded year: 2002
- Headcount: 11-50
- LinkedIn: anp-technologies-inc.
ANP Technologies, Inc. is a biotechnology firm based in Newark, Delaware, founded in 2002. The company focuses on the development of innovative nano-therapeutics and drug delivery systems, catering primarily to pharmaceutical companies and research institutions. ANP has made significant strides in areas such as immunogenicity testing and biodefense. Their portfolio includes products designed for biological and chemical defense, showcasing their commitment to addressing critical health threats. Notably, ANP has developed a nanoencapsulated antibody cocktail aimed at treating Ebola, which received funding for nonhuman primate testing from the U.S. Department of Defense. The company also offers a range of life science products and has achieved ISO 9001:2008 certification for its quality management system, reflecting its dedication to high standards in product development and manufacturing.
22. LimmaTech Biologics AG
- Website: lmtbio.com
- Ownership type: Private
- Headquarters: Schlieren, Zurich, Switzerland
- Employee distribution: Switzerland 92%, United Kingdom (UK) 4%, Sweden 4%
- Founded year: 2015
- Headcount: 51-200
- LinkedIn: limmatech-biologics-ag
LimmaTech Biologics AG, founded in 2015 and based in Schlieren, Zurich, Switzerland, is a biotechnology company dedicated to developing innovative vaccines aimed at combating antimicrobial resistance. The company specializes in multivalent and bioconjugate vaccines, targeting pathogens that pose a significant threat to public health. LimmaTech leverages its proprietary self-adjuvanting and multi-antigen vaccine platform to create effective solutions against increasingly untreatable microbial infections. With a strong focus on research and development, the company is actively engaged in clinical trials for several vaccine candidates, including those targeting Shigella and Staphylococcus aureus. Their mission emphasizes the importance of efficient vaccines in preventing infections and addressing the global challenge of antimicrobial resistance. LimmaTech's team comprises seasoned professionals with extensive experience in vaccine development, further enhancing their capability to deliver impactful solutions in the field of infectious diseases.
23. Emergex Vaccines
- Website: emergexvaccines.com
- Ownership type: Venture Capital
- Headquarters: Abingdon, England, United Kingdom (UK)
- Latest funding: Other (Grant), $667,000, February 2022
- Founded year: 2016
- Headcount: 11-50
- LinkedIn: emergex-vaccines-holding-limited
Emergex Vaccines is a clinical-stage biotechnology firm based in Abingdon, England, specializing in the development of T-cell vaccines aimed at combating viral and bacterial infections. Founded in 2016, the company has established a robust pipeline of synthetic vaccine candidates designed to elicit a strong immune response against significant health threats, such as Dengue Fever and Betacoronaviruses. Their innovative approach utilizes 100% synthetic components to prime the immune system, potentially offering long-lasting protection. Emergex has received funding through grants, with their latest funding round occurring in February 2022. The company operates research and development facilities in the UK and the USA, and actively collaborates with various healthcare organizations and governments to enhance their vaccine offerings. Their commitment to addressing urgent infectious diseases positions them as a relevant player in the biodefense sector.
24. Humabs BioMed, subsidiary of Vir Biotechnology
- Website: humabs.com
- Ownership type: Corporate
- Headquarters: Bellinzona, Ticino, Switzerland
- Employee distribution: Switzerland 100%
- Latest funding: September 2017
- Founded year: 2004
- Headcount: 51-200
- LinkedIn: humabs-biomed
Humabs BioMed, a subsidiary of Vir Biotechnology, is a biopharmaceutical firm based in Bellinzona, Switzerland. Founded in 2004, the company specializes in developing immunotherapies aimed at combating serious infectious diseases. Utilizing its proprietary CellClone technologies, Humabs BioMed focuses on discovering and developing effective treatments for viral and bacterial infections. Their portfolio includes programs targeting major public health threats such as Ebola, Zika, Rabies, and Dengue. The company collaborates with healthcare organizations and government agencies to address unmet medical needs, demonstrating a commitment to public health. With a pipeline that includes over fifteen development candidates, Humabs BioMed is actively engaged in advancing its therapies through early stages of clinical development, showcasing its potential impact in the field of infectious disease treatment.
25. Design West Technologies, Inc.
- Website: dwtusa.com
- Ownership type: Private
- Headquarters: Tustin, California, United States (USA)
- Employee distribution: United States (USA) 100%
- Founded year: 1994
- Headcount: 51-200
- LinkedIn: design-west-technologies-inc
Design West Technologies, Inc. (DWT), founded in 1994 and based in Tustin, California, is a private defense contractor with a workforce of approximately 81 employees. The company specializes in advanced weapons systems and CBRN detection and protection technologies. DWT serves military and government clients, providing innovative solutions that enhance operational effectiveness and safety in defense scenarios. Their product offerings include systems for CBRN understanding, mitigation, and protection, showcasing their expertise in addressing chemical and biological threats. DWT is vertically integrated, managing everything from research and development to manufacturing and testing, which allows them to deliver high-quality products tailored to the needs of their customers. They have established a strong reputation for their work with various branches of the U.S. military and government agencies, focusing on the development of specialized products that meet rigorous military specifications.
26. Vabiotech
- Website: vabiotech.com.vn
- Ownership type: Private
- Headquarters: Trung Hoà, Hanoi, Vietnam
- Founded year: 2000
- Headcount: 1-10
- LinkedIn: vabiotech
Vabiotech, officially known as Công ty TNHH MTV Vắc xin và Sinh phẩm số 1, is a biotechnology firm based in Hanoi, Vietnam. Founded in 2000, the company specializes in the production of vaccines and biological products aimed at enhancing public health. Vabiotech serves healthcare providers and government health departments, ensuring the availability of high-quality vaccines for disease prevention. Their product line includes vaccines for hepatitis A, hepatitis B, Japanese encephalitis, and oral cholera, among others. The company is also engaged in research and development to innovate and improve vaccine technology, which is crucial for addressing emerging health threats. Vabiotech operates under stringent quality standards, including WHO-GMP and ISO 9001:2015 certifications, ensuring that their products meet international safety and efficacy benchmarks.
Biodefense Insights: Key Companies
| Company | Headquarter | Size | Founded | Ownership |
|---|---|---|---|---|
| BioFire Defense | Salt Lake City, Utah, United States (USA) | 51-200 | 1990 | Private |
| Elusys Therapeutics, Inc. | Parsippany-Troy Hills, New Jersey, United States (USA) | 11-50 | 1998 | Corporate |
| Tunnell Government Services, Inc. | Bethesda, Maryland, United States (USA) | 51-200 | 1962 | Private |
| Fabentech | Lyon, Auvergne-Rhône-Alpes, France | 11-50 | 2009 | Venture Capital |
| Mapp Biopharmaceutical Inc | San Diego, California, United States (USA) | 51-200 | 2003 | Private |
| BioFactura, Inc. | Frederick, Maryland, United States (USA) | 11-50 | 2003 | Corporate |
| Greffex, Inc. | Aurora, Colorado, United States (USA) | 11-50 | 1999 | Private |
| Signature Science, LLC | Austin, Texas, United States (USA) | 201-500 | 2001 | Corporate |
| Zeteo Tech, Inc. | Sykesville, Maryland, United States (USA) | 11-50 | 2013 | Private |
| Bharat Biotech | Hyderabad, Telangana, India | 1001-5000 | 1996 | Venture Capital |
| ELT Group | Rome, Lazio, Italy | 501-1000 | 1951 | Private |
| Serum Institute of India Pvt. Ltd. | Pune, Maharashtra, India | 1001-5000 | 1966 | Private |
| PHC Global | United States (USA) | 51-200 | 2020 | Private |
| Proengin | Les Mesnuls, Île-De-France, France | 51-200 | 1972 | Private Equity |
| Centivax | South San Francisco, California, United States (USA) | 11-50 | 2020 | Venture Capital |
| AstriVax Therapeutics | Leuven, Flanders, Belgium | 11-50 | 2022 | Private Equity |
| Auro Vaccines LLC | Pearl River, New York, United States (USA) | 11-50 | 2021 | Corporate |
| Porton Biopharma Ltd | Salisbury, England, United Kingdom (UK) | 51-200 | 2015 | Private |
| Baseimmune | London, England, United Kingdom (UK) | 11-50 | 2019 | Venture Capital |
| Apriori Bio | Boston, Massachusetts, United States (USA) | 11-50 | 2020 | Venture Capital |
| ANP Technologies, Inc. | United States (USA) | 11-50 | 2002 | Private |
| LimmaTech Biologics AG | Schlieren, Zurich, Switzerland | 51-200 | 2015 | Private |
| Emergex Vaccines | Abingdon, England, United Kingdom (UK) | 11-50 | 2016 | Venture Capital |
| Humabs BioMed, subsidiary of Vir Biotechnology | Bellinzona, Ticino, Switzerland | 51-200 | 2004 | Corporate |
| Design West Technologies, Inc. | Tustin, California, United States (USA) | 51-200 | 1994 | Private |
| Vabiotech | Trung Hoà, Hanoi, Vietnam | 1-10 | 2000 | Private |
Want to Find More Biodefense Companies?
If you want to find more companies that focus on vaccines, diagnostics, and biothreat mitigation solutions you can do so with Inven. This list was built with Inven and there are hundreds of companies like these globally.With Inven you'll also get to know the company's:- Detailed Ownership: Who owns the company? Is it a public or private company? What is the ownership structure?
- Contact data: Who are the founders and CEO's? What are their emails and phone numbers?
- Financials: How do these companies perform financially? What are their revenues and profit margins?
...and a lot more!
Trusted by 700+ companies
